(Press-News.org) MIAMI, FLORIDA (Sept. 18, 2023) – Thoracic surgeons and researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine found that increasing numbers of patients undergoing cancer-removal lung surgery by “anatomic lung resections” – lobectomies or segmentectomies – are able to go home safely and without complications one day after the operation, thanks to growing rates of robot-assisted surgeries and improvements in patient-centered care protocols.
However, the research team found, patients of lower socioeconomic status were considerably less likely than others to be discharged on postoperative Day 1 (POD1).
“We believe this is the first study to explore the impact of socioeconomic factors on POD1 discharge in this patient population,” said Dao Nguyen, M.D., Sylvester Thoracic Cancers Group Co-Lead, and senior author of an article in the Sept. 14, 2023, issue of the Journal of Thoracic and Cardiovascular Surgery Open.
“We found that economic deprivation severely affects the ability to be discharged home the day following surgery, an observation that provides future direction for research and the development of improved care strategies and interventions,” added Nguyen, who treats and studies lung and other cancers. The retrospective study of medical records of 750 patients over a 10-year period was launched to document the effects and progress of postoperative care protocols initiated by lung cancer surgeons at Sylvester.
The guidelines, similar to those at other institutions, are called enhanced recovery after thoracic surgery, or ERATS, protocols. The first ERATS initiative was introduced in February 2018, with an optimized version implemented in January 2020. This study focused on findings from 279 patients whose treatment took place during the latest protocol period.
“Patients in the optimized ERATS group had significantly shorter hospital stays, more ‘lung-sparing’ procedures, and lower incidence of complications. Up to 30% of our patients undergoing robotic surgery and having the advantage of our latest ERATS version were discharged home on POD1. This is a significant difference from the less than 5% rate of POD1 discharge prior to the implementation of the optimized ERATS in January 2020,” Nguyen said, adding that ERATS implementation has been associated with a significant reduction of postoperative acute pain and the need for in-hospital opioid medication.
Postoperative Day 1 discharge was a byproduct, not a stated goal, of ERATS, the authors note. The protocol’s emphasis on an enhanced recovery period – in particular, effective opioid-sparing pain control and reduction of complications – brought about accelerated discharges, include those on POD1.
The study was based on the experience of thoracic surgeons, Nguyen and article co-author Nestor Villamizar, M.D. They had seen that POD1 discharge was possible and safe for patients undergoing other chest operations before extending the expedited discharge practice to the lung cancer surgery population.
According to the authors, critical factors making next-day discharge possible are: expedited drain removal, better opioid-sparing pain control, preoperative counseling to discuss realistic postop expectations and home care arrangements, and regular, follow-up phone calls by nurse practitioners to encourage patients and monitor their progress.
Despite the growing number of next-day discharges, Nguyen and colleagues said they saw a 71% decrease in POD1 discharges in patients of lower socioeconomic status, a finding that demands further study. As part of their work, they also analyzed numerous factors contributing to and detracting from POD1 discharge.
“We were able to identify a variety of factors that can be mitigated to facilitate POD1 discharge, and we have instituted strategies to address them,” Nguyen said.
Authors: Nguyen is senior and corresponding author. Daniel Gross, M.D., is first author. In addition to Villamizar, co-authors include: Ahmed Alnajar, M.D., Luis Miguel Cotamo, and Michael Sarris-Michopoulos.
Funding and potential conflicts of interest: The authors declare no conflicts of interest. The authors discuss the off-label use of liposomal bupivacaine (LipoB) (Exparel, Pacira Pharmaceuticals Inc, Parsippany, New Jersey) for intercostal nerve block, used with institutional approval.
Article Title: "Postoperative day 1 discharge following robotic thoracoscopic pulmonary anatomic resections in the era of enhanced recovery protocol: A single-institution experience"
DOI: https://doi.org/10.1016/j.xjon.2023.08.006
# # #
END
A new study finds that creating physical gaps in the forest canopy give eastern hemlocks more access to resources and help those trees withstand infestation by an invasive insect. The approach adds another tool to the toolkit that foresters can use to protect these trees.
Eastern hemlocks are an ecologically important tree species found from eastern Canada to the Great Lakes states and south along the entire Appalachian mountain range. The hemlock woolly adelgid – an invasive insect that was introduced to North America 70 years ago and has spread along the East Coast – can kill a hemlock tree in as little as four years.
“An ...
FOR IMMEDIATE RELEASE
Monday, September 18, 2023
Contact:
Jillian McKoy, jpmckoy@bu.edu
Michael Saunders, msaunder@bu.edu
##
Trump's Anti-Immigrant Rhetoric, Policies Contributed to Decline in Preventive Healthcare Visits among Children of Immigrants
A new study shows that well-child visits for children with immigrant mothers ...
Urbana-Champaign, Illinois/Austin, Texas—[Sept. 18]—Samsung Austin Semiconductor is partnering with The Grainger College of Engineering at the University of Illinois Urbana-Champaign (UIUC) to continue building the talent pipeline needed to support the growing semiconductor ecosystem throughout the United States.
Samsung Austin Semiconductor is announcing a $1 million contribution per year to Grainger Engineering as part of its 5-star workforce development plan to provide support to engineering students who are interested ...
As announced by the Department of Defense today, The University of Texas at Dallas will receive $30 million over three years from the DOD to develop and commercialize new battery technologies and manufacturing processes, enhance the domestic availability of critical raw materials, and train high-quality workers for jobs in an expanding battery energy storage workforce.
The award, which creates a prototype Energy Storage Systems Campus, is the largest allocation from a federal agency that the University has received to date. The Energy Storage Systems Campus will leverage and stimulate over $200 million in private capital.
Dr. Kyeongjae ...
Below please find a summary of a new article that will be published in the next issue of Annals of Internal Medicine. The summary is not intended to substitute for the full article as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.
----------------------------
ACP issues updated Rapid, Living Practice Points on treating COVID-19 patients in outpatient settings
Article: https://www.acpjournals.org/doi/10.7326/M23-1636
Evidence ...
Discovery from the lab of Youyang Zhao, PhD, from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago offers promising treatment approaches for acute respiratory distress syndrome (ARDS) in the elderly that can be caused by severe COVID-19, pneumonia, flu or sepsis. Currently there are no pharmacological or cell-based treatments for ARDS.
Dr. Zhao’s research established that a gene called FOXM1 is important in the repair of blood vessel through regeneration of endothelial cells, which line the vessels of the lung. He found that aging impairs this gene’s expression, ...
Could future opioid overdoses, fatalities and other harms of opioid addiction be prevented if hospital emergency departments made better use of effective medications for opioid addiction?
A team of University of Michigan researchers thinks so.
Led by Thuy Nguyen of U-M's School of Public Health, the researchers analyzed national Medicaid claims data of patients ages 12 to 64 treated at U.S. emergency departments for opioid overdoses in 2018. They focused on ED visits for opioid overdose and the rate of initiation of FDA-approved medications for opioid addiction, including buprenorphine, methadone and extended release naltrexone.
The ...
Among adults with chronic kidney disease (CKD) enrolled in the Chronic Renal Insufficiency Cohort (CRIC), young age, Black race, and low levels of education and income were associated with lower likelihood of getting an annual flu shot.
Identifying risk factors for not receiving a flu vaccine (“non-vaccination”) in people living with kidney disease, who are at risk of flu and its complications, could inform strategies for improving vaccine uptake. In this study published in the American Journal of Kidney Diseases (AJKD), researchers led by Junichi Ishigami examined whether demographic factors, social ...
In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process involves modifying patients’ T-cells to target cancer cells, resulting in remarkable success rates for previously intractable forms of cancer.
Six CAR T cell therapies have secured FDA approval, and several more are in the pipeline. However, these therapies come with severe and potentially lethal side effects, namely cytokine release syndrome (CRS) and neurotoxicity. These drawbacks manifest as a range of symptoms—from high fever and vomiting to multiple ...
EMBARGOED: September 18, 2023 4PM EST
CONTACT: Nicole Oliverio, nicole_oliverio@dfci.harvard.edu, 617-257-0454
Boston – An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that ...
